| Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease (NCT07514338) | Pharming Technologies B.V. | 2026-06-09 |
| Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation (NCT06990529) | Pharming Technologies B.V. | 2025-04-29 |
| Leniolisib for Immune Dysregulation in CVID (NCT06897358) | Pharming Technologies B.V. | 2025-02-12 |
| Leniolisib for Immune Dysregulation in PIDs (NCT06549114) | Pharming Technologies B.V. | 2024-10-21 |
| Pediatric Patients Aged 1 to 6 Years With APDS (NCT05693129) | Pharming Technologies B.V. | 2023-08-30 |
| An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS (NCT06249997) | Pharming Technologies B.V. | 2023-08-03 |
| Pediatric Patients Aged 4 to 11 Years With APDS (NCT05438407) | Pharming Technologies B.V. | 2023-02-01 |
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (NCT05650229) | Pharming Technologies B.V. | 2022-12-13 |
| Prevention of Acute Kidney Injury in Patients With NSTEMI (NCT04912141) | Pharming Technologies B.V. | 2021-04-21 |
| Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 (NCT04530136) | Pharming Technologies B.V. | 2020-11-30 |
| Patient Registry to Evaluate the Real-world Safety of Ruconest® (NCT03697187) | Pharming Technologies B.V. | 2018-06-30 |
| Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI (NCT02859727) | Pharming Technologies B.V. | 2016-09-08 |
| A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor (NCT02247739) | Pharming Technologies B.V. | 2014-12-01 |
| Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients (NCT01359969) | Pharming Technologies B.V. | 2012-01-17 |
| C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks (NCT01397864) | Pharming Technologies B.V. | 2011-07-01 |
| Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks (NCT01188564) | Pharming Technologies B.V. | 2011-01-01 |
| Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation (NCT01035593) | Pharming Technologies B.V. | 2010-12-01 |
| A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (NCT00851409) | Pharming Technologies B.V. | 2009-06-01 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (NCT00225147) | Pharming Technologies B.V. | 2005-07-01 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (NCT00262301) | Pharming Technologies B.V. | 2004-06-01 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (NCT00262288) | Pharming Technologies B.V. | 2004-04-01 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (NCT00261053) | Pharming Technologies B.V. | 2003-06-01 |